Anticipated FDA Approval of Agios Pharma’s Pyrukynd Expected to Boost Stock Value

Agios Pharma, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on the stock and has a $48.00 price target.

Emily Bodnar’s rating is based on the expectation that Agios Pharma’s Pyrukynd, a treatment for thalassemia, is likely to receive FDA approval despite a delay in the decision-making process. The delay is attributed to administrative issues rather than concerns about the drug’s safety or efficacy, which supports confidence in its eventual approval.
The FDA’s history of missing PDUFA goal dates in 2025, often due to workload and resource constraints, further supports the likelihood of approval. Similar cases have resulted in approvals after a reasonable delay, and Agios has not been asked for additional safety or efficacy data, which is a positive indicator. Therefore, Emily anticipates that the approval of Pyrukynd could lead to a significant increase in Agios Pharma’s stock value.

According to TipRanks, Bodnar is a 4-star analyst with an average return of 13.5% and a 35.89% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Atossa Therapeutics, AnaptysBio, and Olema Pharmaceuticals.

In another report released today, Bank of America Securities also reiterated a Buy rating on the stock with a $32.00 price target.